Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

By LabMedica International staff writers
Posted on 19 May 2025

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. More...

However, more than 90% of physician offices in the U.S. lack the necessary infrastructure to perform on-site CBC testing, often resulting in delayed results and missed diagnostic opportunities during patient consultations. Now, a new cartridge-based CBC test is expanding access to quick results in physician offices, pharmacies, and home care settings, making data-driven diagnostics more accessible.

CytoChip’s (Irvine, CA, USA) CitoCBC is a cartridge-based CBC system that allows healthcare professionals to quickly perform accurate CBC testing not only in hospitals but also in physician offices, pharmacies, nursing homes, and other places where CBC testing was previously unavailable. CitoCBC is designed to offer both ease of use and high performance. The self-contained cartridge simplifies the testing process, providing a comprehensive 5-part differential CBC with a turnaround time of just eight minutes. On-screen, step-by-step instructions guide users through the process, even if they have no laboratory experience. The system includes advanced features, such as Optical Fluorescent Platelet (OFP) detection, which surpasses the capabilities of many traditional lab analyzers. The analyzer also conducts periodic self-checks to ensure its functionality. Test results can be displayed on-screen, printed out, or transmitted via connection to a laboratory information system (LIS). In comparisons to state-of-the-art CBC solutions used in hospitals and clinical labs, the performance of CitoCBC has proven to be substantially equivalent. The CBC counts produced meet the rigorous CLIA 2024 Proficient Testing standards for hematology.

The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance and a CLIA Waiver for CitoCBC, making it the first cartridge-based CBC test to achieve this milestone. This breakthrough significantly increases access to CBC testing in decentralized healthcare environments like physician offices, pharmacies, and home care settings. The CLIA Waiver eliminates testing barriers, allowing for fast, reliable CBC results in a compact device, which ultimately improves patient care and supports better clinical decision-making. With FDA clearance and a CLIA waiver, CitoCBC ensures accuracy and reliability, allowing non-laboratory personnel to operate the system effectively. Overall, CitoCBC provides state-of-the-art testing with a small footprint, requiring minimal staff training and lower capital investment. The product will first launch in the United States and later expand to select European countries upon obtaining the CE Marking.

"Achieving CLIA Waiver for a CBC test is a major step forward in improving access to diagnostics at the point of care," said Dr. Wendian Shi, CEO of CytoChip. "This milestone not only fills a critical gap among CLIA Waived testing but also expands diagnostic accessibility in underserved areas."

Related Links:
CytoChip


New
Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Capillary Blood Collection Tube
IMPROMINI M3
New
Human Estradiol Assay
Human Estradiol CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Pathology

view channel
image: Researchers Marco Gustav (right) and MD Nic G. Reitsam (left) discuss the study data (Photo courtesy of Anja Stübner/EKFZ)

AI Model Simultaneously Detects Multiple Genetic Colorectal Cancer Markers in Tissue Samples

Colorectal cancer is a complex disease influenced by multiple genetic alterations. Traditionally, studies and diagnostic tools have focused on predicting only one mutation at a time, overlooking the interplay... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.